Ivacaftor Safe in CF Infants Aged 1 to 4 Months
A phase 3 clinical trial, ivacaftor (Kalydeco, Vertex Pharma) was generally safe to administer to infants aged 1-month to <4-months old, according to research published in Journal of Cystic Fibrosis.
Tag: ivacaftor Kalydeco
All
Latest
All
Latest
Kalydeco Approved for Kids 12-23 Months with Cystic Fibrosis
Kalydeco (ivacaftor) has been approved by the FDA for children with cystic fibrosis (CF) ages 12 to <24 months who have at least one mutation in their CFTR gene.
All
LatestArkansas Medicaid Settles Federal Lawsuit Over CF Drug Kalydeco
Arkansas Medicaid has settled a federal lawsuit brought by patients denied the cystic fibrosis (CF) drug Kalydeco due its high cost.
Kalydeco Wins The Wall Street Journal’s 2012 Technology Innovation Award
The drug, known to treat the underlying cause of cystic fibrosis, is recognized for having a wide impact in its field.
Read MoreVertex Expanding Studies of Kalydeco to More CF Patient Groups
The company announced plans to begin clinical trials of the potential cystic fibrosis therapy Kalydeco (VX-770) in more patient groups–including children as young as 2 years old–later this year.
Read More